Posted On: 11/15/2016 10:16:49 AM
Post# of 72447
Leo says: "There is much greater value in the anti-inflammatory" effect of Brilacidin.
Stressing that the LOWEST level helped the UP patients, and it was undetectable in the bloodstream -- minimal systemic exposure.
"We think that the latest data increases the value of Brilacidin many-fold."
Bril-OM, they're optimistic, more data in first half of 2017.
Kevetrin, phase 2A trial for ovarian cancer. Want to see exactly how K modulates p53 in the tumor. Oral formulation -- very exciting. Phase 1 was once a week by infusion. If they can take pill 2 or 3 times a day, 7 days a week -- they are excited.
Prurisol: was our dark horse. Following 2 successful clinical trials and a phase 2B PHARMAS ARE BEGINNING TO RECOGNIZE the value of Prurisol. HINT HINT !
psoriasis AND OTHER autoimmune disorders.
we're ahead of a rival drug
value of P could easily exceed current market cap
new possibilities cropping up from other things in intellectual property.
Stressing that the LOWEST level helped the UP patients, and it was undetectable in the bloodstream -- minimal systemic exposure.
"We think that the latest data increases the value of Brilacidin many-fold."
Bril-OM, they're optimistic, more data in first half of 2017.
Kevetrin, phase 2A trial for ovarian cancer. Want to see exactly how K modulates p53 in the tumor. Oral formulation -- very exciting. Phase 1 was once a week by infusion. If they can take pill 2 or 3 times a day, 7 days a week -- they are excited.
Prurisol: was our dark horse. Following 2 successful clinical trials and a phase 2B PHARMAS ARE BEGINNING TO RECOGNIZE the value of Prurisol. HINT HINT !
psoriasis AND OTHER autoimmune disorders.
we're ahead of a rival drug
value of P could easily exceed current market cap
new possibilities cropping up from other things in intellectual property.
(0)
(0)
